Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

News and Events

For additional information, please contact info@cardiffoncology.com. or call 1-858-952-7593

Cardiff Oncology Chief Executive Officer, Dr. Mark Erlander, and Chief Financial Officer, James Levine will participate in the H.C. Wainwright Investment Conference September 13th - 15th, 2021....

Cardiff Oncology Chief Executive Officer, Dr. Mark Erlander, and Chief Financial Officer, James Levine will participate in the H.C. Wainwright Investment Conference September 13th - 15th, 2021....

Cardiff Oncology Chief Executive Officer, Mark Erlander, and Chief Financial Officer, James Levine, will participate in the H.C. Wainwright Global Investment Conference Monday, September 13th...